Patents by Inventor Jagdish A. Desai

Jagdish A. Desai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYMORPHIC FORMS OF LOMITAPIDE AND ITS SALTS AND PROCESSES FOR THEIR PREPARATION
    Publication number: 20160083345
    Abstract: The present invention relates to various polymorphic forms of lomitapide or its salts and processes for preparation thereof. The present invention provides Lomitapide mesylate in solid amorphous form and process for preparation thereof. The invention also provides an amorphous solid dispersion of lomitapide mesylate. Further, various crystalline forms of lomitapide mesylate like A, B and C and process for preparation thereof are provided. The invention also provides crystalline forms of lomitapide free base, in particular Form I and Form-II and their preparation. The invention further provides compositions comprising various forms of lomitapide and its salts.
    Type: Application
    Filed: September 18, 2015
    Publication date: March 24, 2016
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Sanjay Jagdish DESAI, Brij KHERA, Jagdish Maganlal PATEL, Harshita Bharatkumar SHAH, Arunkumar Shyam Narayan UPADHYAY, Sureshkumar Narbheram AGRAVAT
  • PROCESS FOR THE PREPARATION OF PERAMPANEL
    Publication number: 20160039759
    Abstract: The present invention relates to processes for the preparation of perampanel and its intermediates.
    Type: Application
    Filed: August 3, 2015
    Publication date: February 11, 2016
    Inventors: Sanjay Jagdish DESAI, Jayprakash Ajitsingh Parihar, Kuldeep Natwarlal Jain, Sachin Ashokrao Patil
  • PROCESS FOR PREPARATION AND PURIFICATION OF CANAGLIFLOZIN
    Publication number: 20160002275
    Abstract: The present invention provides a canagliflozin complex. The complex is provided with an adsorbent selected from activated carbon, silica gel, ionic or non-ionic polymer and a cyclodextrin or derivatives thereof. The invention also provides a process for the preparation of canagliflozin and its intermediates thereof. The invention further provides a process for the purification of canagliflozin.
    Type: Application
    Filed: June 30, 2015
    Publication date: January 7, 2016
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Sanjay Jagdish DESAI, Jayprakash Ajitsingh PARIHAR, Jagdish Maganlal PATEL, Uday Suresh SURYAWANSHI, Jaisukh Bhupatbhai BHALALA
  • AMORPHOUS FORM OF DAPAGLIFLOZIN 1,2-PROPANEDIOL
    Publication number: 20150307540
    Abstract: The invention provides an amorphous form of dapagliflozin 1,2-propanediol of Formula (A) or hydrates thereof and their process for preparation. The present invention also provides a pharmaceutical composition comprising art amorphous solid dispersion containing dapagliflozin 1,2-propanediol or hydrates thereof.
    Type: Application
    Filed: February 19, 2015
    Publication date: October 29, 2015
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Shri Prakash Dhar DWIVEDI, Brij KHERA, Jagdish Maganlal PATEL, Sanjay Jagdish DESAI, Jayprakash Ajitsingh PARIHAR, Mahesh Laljibhai RUPAPARA
  • PROCESS FOR THE PREPARATION OF FULVESTRANT
    Publication number: 20150291652
    Abstract: The present invention relates to an improved process for the preparation of Fulvestrant (I). Also, provided is novel intermediate of Fulvestrant and a process for the preparation of the same.
    Type: Application
    Filed: October 11, 2013
    Publication date: October 15, 2015
    Inventors: Mettilda Lourdusamy, Ioan Iosif Radu, Brijesh Dinkarrai Desai, Pramod Bhagvanjibhai Pansuriya, Sanjay Jagdish Desai
  • Compounds that are ERK inhibitors
    Patent number: 8999966
    Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl ring, or a monocyclic heterocycloalkenyl ring, or a bridged monocyclic heterocycloalkyl ring, or a fused (monocyclic heterocycloalkyl ring) cyclopropyl ring. Also disclosed are methods of treating cancer using the compounds of formula (1).
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: April 7, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Sobhana Babu Boga, Joseph M. Kelly, Hugh Y. Zhu, Abdul-Basit Alhassan, Xin Yao, Xiaolei Gao, James J-S Wang, Jagdish A. Desai, Subrahmanyam Gudipati, Sie-Mun Lo, Liang Zhu, Alan B. Cooper, Yongqi Deng, Gerald W. Shipps, Jr.
  • Compounds that are ERK inhibitors
    Patent number: 8716483
    Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydropyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: May 6, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Alan B. Cooper, Yang Nan, Yongqi Deng, Gerald W. Shipps, Jr., Neng-Yang Shih, Hugh Y. Zhu, Jagdish A. Desai, James J-S Wang, Sunil Paliwal, Hon-Chung Tsui, Sobhana Babu Boga, Abdul-Basit Alhassan, Xiaolei Gao, Liang Zhu, Ahmed Samatar
  • Compounds that are ERK inhibitors
    Patent number: 8658651
    Abstract: Disclosed are the ERK inhibitors of formula 1.0: (Formula (A1)), and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine ring that can have a bridge or a fused ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula A1.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: February 25, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Hugh Y. Zhu, Jagdish A. Desai, Alan B. Cooper, Ronald J. Doll
  • Compounds that are ERK inhibitors
    Patent number: 8546404
    Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
    Type: Grant
    Filed: June 5, 2007
    Date of Patent: October 1, 2013
    Assignee: Merck Sharp & Dohme
    Inventors: Alan B. Cooper, Yongqi Deng, Gerald W. Shipps, Jr., Neng-Yang Shih, Hugh Y. Zhu, Robert Sun, Joseph M. Kelly, Ronald J. Doll, Yang Nan, Tong Wang, Jagdish A. Desai, James J-S Wang, Youhao Dong, Vincent S. Madison, Li Xiao, Alan W. Hruza, M. Arshad Siddiqui, Ahmed A. Samatar, Sunil Paliwal, Hon-Chung Tsui, Azim Alan Celebi, Yiji Wu, Sobhana Babu Boga, Abdul-Basit Alhassan, Xiaolei Gao, Liang Zhu, Mehul Patel
  • NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
    Publication number: 20130237518
    Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl ring, or a monocyclic heterocycloalkenyl ring, or a bridged monocyclic heterocycloalkyl ring, or a fused (monocyclic heterocycloalkyl ring) cyclopropyl ring. Also disclosed are methods of treating cancer using the compounds of formula (1).
    Type: Application
    Filed: October 24, 2011
    Publication date: September 12, 2013
    Inventors: Sobhana Babu Boga, Joseph M. Kelly, Hugh Y. Zhu, Abdul-Basit Alhassan, Xin Yao, Xiaolei Gao, James J-S Wang, Jagdish A. Desai, Subrahmanyam Gudipati, Sie-Mun Lo, Liang Zhu, Alan B. Cooper, Yongqi Deng, Gerald W. Shipps, JR.
  • NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
    Publication number: 20120214823
    Abstract: Disclosed are the ERK inhibitors of formula 1.0: (Formula (A1)), and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine ring that can have a bridge or a fused ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula A1.
    Type: Application
    Filed: September 20, 2010
    Publication date: August 23, 2012
    Inventors: Hugh Y. Zhu, Jagdish A. Desai, Alan B. Cooper, Ronald J. Doll
  • PROCESS FOR PREPARATION OF PHENOLIC MONOESTERS OF HYDROXYMETHYL PHENOLS
    Publication number: 20110282094
    Abstract: A process for the preparation of phenolic monoesters of 2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol by converting (±)6-halo-4-phenylchroman-2-one to (±)4-halo-2-(3-hydroxy-1-phenylpropyl)phenol. The two hydroxyl groups are protected and the protected compound is reacted with diisopropylamine to give (±)[3-(2-benzyloxy-5-halophenyl)-3-phenylpropyl]diisopropylamine. The halo substituent on the benzene ring is converted to corresponding benzyl alcohol and then the protection is removed to give racemic 5-HMT. Racemic 5-HMT is converted R enantiomer and then it is esterified.
    Type: Application
    Filed: May 10, 2011
    Publication date: November 17, 2011
    Applicant: INTAS PHARMACEUTICALS LIMITED
    Inventors: Sanjay Jagdish DESAI, Kalpesh Mahendrabhai PATEL, Aakash Maheshkumar SHAH, Ranjit Shardulbhai PADA, Hitesh Manubhai MAKWANA
  • NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
    Publication number: 20110189192
    Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydropyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
    Type: Application
    Filed: February 19, 2009
    Publication date: August 4, 2011
    Inventors: Alan B. Cooper, Yang Nan, Yongqi Deng, Gerald W. Shipps, JR., Neng-Yang Shih, Hugh Y. Zhu, Joseph M. Kelly, Subrahmanyam Gudipati, Ronald J. Doll, Mehul F. Patel, Jagdish A. Desai, James J-S Wang, Sunil Paliwal, Hon-Chung Tsui, Sobhana Babu Boga, Abdul-Basit Alhassan, Xiaolei Gao, Liang Zhu, Xin Yao
  • Compounds that are ERK inhibitors
    Patent number: 7807672
    Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substituents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
    Type: Grant
    Filed: February 13, 2007
    Date of Patent: October 5, 2010
    Assignee: Schering Corporation
    Inventors: Yongqi Deng, Gerald W. Shipps, Jr., Alan Cooper, Yang Nan, Tong Wang, M. Arshad Siddiqui, Hugh Zhu, Robert Sun, Joseph M. Kelly, Ronald Doll, Jagdish Desai, James J-S Wang, Youhao Dong, Vincent Madison, Li Xiao, Alan Hruza, Neng-Yang Shih
  • Farnesyl protein transferase inhibitors as antitumor agents
    Patent number: 7557107
    Abstract: Disclosed are novel tricyclic compounds of the formula: and a pharmaceutically acceptable salts or solvates thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are uses of the compounds of formula (I) for the manufacture of a medicament for the treatment of cancer.
    Type: Grant
    Filed: August 4, 2004
    Date of Patent: July 7, 2009
    Assignee: Schering Coporation
    Inventors: Hugh Y. Zhu, Alan B. Cooper, Jagdish A. Desai, James J-S Wang, Ronald J. Doll, F. George Njoroge, Viyyoor M. Girijavallabhan
  • Novel compounds that are ERK inhibitors
    Publication number: 20090118284
    Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
    Type: Application
    Filed: June 5, 2007
    Publication date: May 7, 2009
    Inventors: Alan B. Cooper, Yongqi Deng, Gerald W. Shipps, JR., Neng-Yang Shih, Hugh Y. Zhu, Robert Sun, Joseph M. Kelly, Ronald J. Doll, Yang Nan, Tong Wang, Jagdish A. Desai, James J-S Wang, Youhao Dong, Vincent S. Madison, Li Xiao, Alan W. Hruza, M. Arshad Siddiqui, Ahmed A. Samatar, Sunil Paliwal, Hon-Chung Tsui, Azim Alan Celebi, Yiji Wu, Sobhana Babu Boga, Abdul-Basit Alhassan, Xiaolei Gao, Liang Zhu, Mehul Patel
  • Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents
    Patent number: 7425640
    Abstract: The present invention provides compounds of formula I wherein X, Y, R1-R7 are as defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA polymerase and treating hepatitis C and related disorders using these compounds and compositions are also provided.
    Type: Grant
    Filed: October 26, 2005
    Date of Patent: September 16, 2008
    Assignee: Schering Corporation
    Inventors: Alan B. Cooper, Hugh Y. Zhu, James J-S Wang, Jagdish A. Desai, Gerald W. Shipps, Jr., Patrick J. Curran, D. Allen Annis, Huw M. Nash, Viyyoor M. Girijavallabhan
  • Farnesyl protein transferase inhibitors as antitumor agents
    Patent number: 7342016
    Abstract: Disclosed are novel tricyclic compounds represented by the formula (1.0): and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: March 11, 2008
    Assignees: Schering Corporation, Pharmacopeia, Inc.
    Inventors: Hugh Y. Zhu, F. George Njoroge, Alan B. Cooper, Timothy J. Guzi, Dinanath F. Rane, Keith P. Minor, Ronald J. Doll, Viyyoor M. Girijavallabhan, Bama Santhanam, Patrick A. Pinto, Bancha Vibulbhan, Kartik M. Keertikar, Carmen S. Alvarez, John J. Baldwin, Ge Li, Chia-Yu Huang, Ray A. James, James J-S Wang, Jagdish A. Desai
  • Novel compounds that are ERK inhibitors
    Publication number: 20070232610
    Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
    Type: Application
    Filed: February 13, 2007
    Publication date: October 4, 2007
    Inventors: Yongqi Deng, Gerald Shipps, Alan Cooper, Yang Nan, Tong Wang, M. Siddiqui, Hugh Zhu, Robert Sun, Joseph Kelly, Ronald Doll, Jagdish Desai, James Wang, Youhao Dong, Vincent Madison, Li Xiao, Alan Hruza, Neng-Yang Shih
  • Novel compounds that are ERK inhibitors
    Publication number: 20070191604
    Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
    Type: Application
    Filed: December 11, 2006
    Publication date: August 16, 2007
    Inventors: Alan Cooper, Yongqi Deng, Gerald Shipps, Neng-Yang Shih, Hugh Zhu, Robert Sun, Joseph Kelly, Ronald Doll, Yang Nan, Tong Wang, Jagdish Desai, James Wang, Youhao Dong, Vincent Madison, Li Xiao, Alan Hruza, M. Siddiqui, Ahmed Samatar, Sunil Paliwal, Hon-Chung Tsui, Azim Celebi, Yiji Wu, Sobhana Boga